Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewVIVEbiotech adds newest in vivo lentiviral vector-based therapeutic programs
Now advancing 15 next-generation in vivo therapies through high performance, scalable lentiviral vector manufacturing capabilities.
-
NewBiotech sector reaches record investment levels, surpassing €400 million
Investment in R&D by the biotechnology sector increased by 13.9%, reaching €1.46 billion.
-
Press releaseBiotech sector reaches record investment levels, surpassing €400 million
In 2024, the activity of biotech companies in Spain generated more than €13.27 billion in income, representing 1.2% of the national GDP. Investment in R&D by the biotechnology sector increased by 13.9
-
-
NewJuan Bueren will share at BIOSPAIN 2026 the key insights on how to turn research into life...
Juan Bueren will be one of the keynote speakers at BIOSPAIN 2026, held in Bilbao from September 29 to October 1, the leading biotechnology event in Southern Europe.
-
EventFestival of Biologics
-
EventBIOTECHX USA
-
EventAdvanced Therapies USA
-
NewThe BIOSPAIN 2026 Talent Day will strengthen the connection between companies and professi...
The initiative, which will take place on 1 October, will provide an exclusive space for companies and candidates to connect directly, explore new career opportunities, and address the main talent
-
NewPloid AI: Agentic AI platform to accelerate bioinformatics in life sciences
What used to take days or weeks now takes hours. Ploid AI enables R&D teams to run complex multiomics analyses and automatically generate insights (e.g., publication-ready scientific reports, complex
-
-
NewNatac positions itself among the world's growth companies
The company has been included in the World’s Growth Leaders ranking compiled by TIME magazine and Statista, which highlights the publicly traded companies with the strongest growth and financial
-
NewORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential t...
Oryzon Genomics, a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating
-
NewBioClonal seeks strategic partnerships to advance its Alzheimer’s antibody program and ant...
Spanish biotechnology company BioClonal is advancing a proprietary monoclonal antibody program targeting a novel Alzheimer’s disease-related target and will leverage its participation at BIO
-
Press release
The combination of biotechnology, biomarkers and clinical research is driving a new era in...
Biotechnology is redefining the approach to multiple sclerosis through new therapeutic tools, a more precise understanding of the underlying immunological mechanisms, and strategies aimed not only at
-
NewWorld Multiple Sclerosis Day | “Biotechnology is enabling progress toward a better underst...
On the occasion of World Multiple Sclerosis Day, we interviewed Sanofi, which has a research line specifically focused on chronic neuroinflammation and its role in disease progression, seeking new
-
CompanyMICROSEI BIOTECH
-
NewThe Biotech Act drives the debate on the future of European biomedical innovation
From AseBio, we organized the panel entitled ‘European Biotechnology Act: an opportunity to consolidate Spain as a hub for biotechnological innovation’, within the framework of the XIX Annual
-
Press release
The Biotech Act drives the debate on the future of European biomedical innovation
From AseBio, we organized the panel entitled ‘European Biotechnology Act: an opportunity to consolidate Spain as a hub for biotechnological innovation’, within the framework of the XIX Annual
-
NewMedTech Barcelona to Attend BIO International Convention 2026 in San Diego
MedTech Barcelona will attend the BIO International Convention 2026, which will take place from June 22 to 25 at the San Diego Convention Center, in collaboration with ICEX. The company’s
-
NewBeyond Evidence: The Challenge of Communicating Value in Biotechnology
Spain is already generating science and innovation in biotechnology. The next challenge is not to produce more evidence, but to translate it into clear, decision-relevant value by connecting health
